Drug Profile


Alternative Names: BMS 646256; SLV-319

Latest Information Update: 18 Nov 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Solvay
  • Class Antipsychotics; Imides; Obesity therapies; Pyrazoles; Small molecules; Sulfonamides
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity; Psychotic disorders

Most Recent Events

  • 17 Nov 2008 Discontinued - Phase-II for Obesity in USA (PO)
  • 08 Nov 2006 Phase-II clinical trials in Obesity in USA (unspecified route)
  • 17 Oct 2006 Solvay has completed phase I studies in Obesity in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top